

**Table 13.6a**  
**Immunosuppression Use for Induction, 1998 to 2007**  
**Recipients with Heart-Lung Transplants**

	Year of Transplant									
	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>Transplants</b>	47	51	48	27	33	29	40	35	31	29
<b>With Immunosuppression Info</b>	45	50	48	26	33	28	38	33	30	27
<b>Induction Drugs</b>										
ALG	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	20.0%	16.0%	29.2%	26.9%	15.2%	3.6%	13.2%	12.1%	3.3%	33.3%
OKT3	6.7%	10.0%	6.3%	0.0%	6.1%	3.6%	2.6%	3.0%	0.0%	7.4%
Thymoglobulin	0.0%	4.0%	4.2%	11.5%	3.0%	10.7%	13.2%	3.0%	6.7%	0.0%
Zenapax	0.0%	4.0%	12.5%	7.7%	15.2%	7.1%	18.4%	12.1%	16.7%	11.1%
Simulect	0.0%	0.0%	4.2%	30.8%	18.2%	17.9%	10.5%	24.2%	10.0%	25.9%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	5.3%	9.1%	23.3%	18.5%
<b>No Induction Drugs Recorded</b>	75.6%	66.0%	47.9%	26.9%	42.4%	57.1%	42.1%	39.4%	40.0%	18.5%

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.